NYSE:PFEPfizer Stock Price, Forecast & News

$38.18

+0.77 (+2.06 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$37.72

Now: $38.18▼

$38.44

50-Day Range

$33.61

MA: $37.01▼

$38.51

52-Week Range

$27.88

Now: $38.18▼

$44.56

Volume21.37 million shs

Average Volume28.82 million shs

Market Capitalization$212.08 billion

P/E Ratio13.64

Dividend Yield4.06%

Beta0.71

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 5 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.39, Pfizer has a potential upside of 8.4% from its current price of $38.18.
Amount of Analyst Coverage
Pfizer has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
Pfizer has received 1,358 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pfizer has received 992 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pfizer has received 57.79% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote “Outperform” if you believe PFE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
Pfizer is a leading dividend payer. It pays a dividend yield of 4.06%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pfizer has been increasing its dividend for 10 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 51.53 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 56.09 % next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have bought 96.55% more of their company's stock than they have sold. Specifically, they have bought $5,000,000.00 in company stock and sold $2,543,891.00 in company stock.
Percentage Held by Insiders
Only 0.08% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
70.21% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to decrease by -3.56% in the coming year, from $2.81 to $2.71 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 13.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.97.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 13.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.32.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

3.07 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:PFE

Previous Symbol

CUSIP71708110

CIK78003

Webwww.pfizer.com

Phone212-733-2323

Debt

Debt-to-Equity Ratio0.56

Current Ratio1.02

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio13.64

Forward P/E Ratio13.59

P/E Growth2.74

Sales & Book Value

Annual Sales$51.75 billion

Price / Sales4.10

Cash Flow$4.19 per share

Price / Cash Flow9.12

Book Value$11.76 per share

Price / Book3.25

Profitability

EPS (Most Recent Fiscal Year)$2.95

Net Income$16.27 billion

Net Margins31.17%

Return on Equity25.76%

Return on Assets9.91%

Miscellaneous

Employees88,300

Outstanding Shares5,554,834,000

Market Cap$212.08 billion

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Pfizer (NYSE:PFE) Frequently Asked Questions

How has Pfizer's stock been impacted by COVID-19 (Coronavirus)?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PFE stock has increased by 18.7% and is now trading at $38.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pfizer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Pfizer.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, April, 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.09. The biopharmaceutical company had revenue of $12.03 billion for the quarter, compared to analyst estimates of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. Pfizer's revenue for the quarter was down 8.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.85 EPS. View Pfizer's earnings history.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, April 23rd. Stockholders of record on Friday, May 8th will be given a dividend of $0.38 per share on Friday, June 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.98%. The ex-dividend date of this dividend is Thursday, May 7th. View Pfizer's dividend history.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has authorized a share buyback plan on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 3.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY20 earnings guidance on Tuesday, April, 28th. The company provided earnings per share guidance of $2.82-2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.70. The company issued revenue guidance of $48.5-50.5 billion, compared to the consensus revenue estimate of $47.01 billion.

What price target have analysts set for PFE?

12 Wall Street analysts have issued twelve-month target prices for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $41.39 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View analysts' price targets for Pfizer.

Has Pfizer been receiving favorable news coverage?

Headlines about PFE stock have trended positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the near future. View the latest news aboutPfizer.

Who are some of Pfizer's key competitors?

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), AbbVie (ABBV), General Electric (GE), Walt Disney (DIS), Bank of America (BAC) and Exxon Mobil (XOM).

Who are Pfizer's key executives?

Pfizer's management team includes the following people:

Mr. Ian C. Read, Exec. Chairman (Age 65)
Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.64%), State Street Corp (5.27%), Capital World Investors (4.05%), Wellington Management Group LLP (3.94%), Geode Capital Management LLC (1.62%) and Bank of New York Mellon Corp (1.01%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Jennifer B Damico, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Capital International Investors, Massachusetts Financial Services Co. MA, Two Sigma Advisers LP, Bank of New York Mellon Corp, Schroder Investment Management Group, Alliancebernstein L.P., and AQR Capital Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Douglas M Lankler, Frank A Damelio, and Jennifer B Damico. View insider buying and selling activity for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Wellington Management Group LLP, APG Asset Management N.V., Nuveen Asset Management LLC, Swiss National Bank, APG Asset Management N.V., Advisor Group Holdings Inc., and Invesco Ltd.. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $38.18.

How big of a company is Pfizer?

Pfizer has a market capitalization of $212.08 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

This page was last updated on 5/28/2020 by MarketBeat.com Staff